<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Gemcitabine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00441</strong>&#160; (APRD00201)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar&#174; by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during <span class="caps">DNA</span> replication. The process arrests tumor growth, as new nucleosides cannot be attached to the &#8220;faulty&#8221; nucleoside, resulting in apoptosis (cellular &#8220;suicide&#8221;).<br>
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00441/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00441/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00441.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00441.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00441.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00441.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00441.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00441">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Gemcitabin</td><td>German</td><td>INN</td></tr><tr><td>Gemcitabina</td><td>Spanish</td><td>INN</td></tr><tr><td>Gemcitabine</td><td>French</td><td>INN/USAN</td></tr><tr><td>Gemcitabinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Gemcitabine Hydrochloride</strong>
          <div class="cas">122111-03-9</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000092/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000092/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OKKDEIYWILRZIA-OSZBKLCCSA-N</li>
              <li>Monoisotopic Mass: 299.048440004</li>
              <li>Average Mass: 299.659</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000092">DBSALT000092</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abine</td><td>Dosa</td></tr><tr><td>Abingem</td><td>Miracalus</td></tr><tr><td>Acytabin</td><td>Intas</td></tr><tr><td>Celgem</td><td>Alkem</td></tr><tr><td>Celzar</td><td>Celon</td></tr><tr><td>Cytogem</td><td>Dr Reddys</td></tr><tr><td>Daplax</td><td>Dr Reddys</td></tr><tr><td>Dercin</td><td>Egis</td></tr><tr><td>Eriogem</td><td>Eriochem</td></tr><tr><td>Fotinex</td><td>Fada</td></tr><tr><td>Gebina</td><td>Aspen</td></tr><tr><td>Gembio</td><td>Bioprofarma</td></tr><tr><td>Gemcired</td><td>Dr Reddys</td></tr><tr><td>Gemita</td><td>Fresenius</td></tr><tr><td>Gemzar</td><td>Lilly</td></tr><tr><td>Gezt</td><td>Richmond</td></tr><tr><td>Gitrabin</td><td>Actavis</td></tr><tr><td>Gramagen</td><td>Lilly</td></tr><tr><td>Jemta</td><td>Sandoz</td></tr><tr><td>Nallian</td><td>Gedeon Richter</td></tr><tr><td>Oncogem</td><td>Grey Inversiones</td></tr><tr><td>Ribozar</td><td>Ribosepharm</td></tr><tr><td>Tabin</td><td>Crinos</td></tr><tr><td>Xtroz</td><td>Ranbaxy</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiviral-agents">Antiviral Agents</a></li>
<li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/antimetabolites-antineoplastic">Antimetabolites, Antineoplastic</a></li>
<li><a href="/mesh/radiation-sensitizing-agents">Radiation-Sensitizing Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>95058-81-4</td></tr><tr><th>Weight</th><td>Average: 263.1981<br>Monoisotopic: 263.071762265</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>SDUQYLNIPVEERB-QPPQHZFASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Pyrimidine 2'-deoxyribonucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Pentoses; Pyrimidones; Aminopyrimidines and Derivatives; Primary Aromatic Amines; Hydropyrimidines; Tetrahydrofurans; Oxolanes; Fluorohydrins; Secondary Alcohols; Ethers; Polyamines; Primary Alcohols; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>pentose monosaccharide; pyrimidone; aminopyrimidine; primary aromatic amine; hydropyrimidine; monosaccharide; pyrimidine; oxolane; tetrahydrofuran; fluorohydrin; secondary alcohol; halohydrin; ether; primary alcohol; polyamine; organonitrogen compound; alcohol; organofluoride; organohalogen; primary amine; amine; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrimidine 2'-deoxyribonucleosides and analogues. These are compounds consisting of a pyrimidine linked to a ribose which lacks an hydroxyl group at position 2.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. </td></tr><tr><th>Pharmacodynamics</th><td>Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand. It demonstrates dose-dependent synergistic activity with cisplatin in vitro. In vivo, gemcitabine showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Gemcitabine was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.</td></tr><tr><th>Mechanism of action</th><td>Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.</td></tr><tr><th>Absorption</th><td>The pharmacokinetics of gemcitabine are described by a 2-compartment model. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>50 L/m^2 [infusions lasting &lt;70 minutes]</li>
	<li>370 L/m^2 [long infusions]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Plasma protein binding is negligible (</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Transformed via nucleoside kinases to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Can also undergo deamination via cytidine deaminase to an inactive uracil metabolite (dFdU).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Gemcitabine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002804" target="_blank">Deoxycytidine kinase</a></li></ul></td><td><a href="/metabolites/DBMET01145">Gemcitabine Monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1269">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01145">Gemcitabine Monophosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004700" target="_blank">Deoxycytidylate deaminase</a></li></ul></td><td><a href="/metabolites/DBMET00694">Difluorodeoxyuridine monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1270">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01145">Gemcitabine Monophosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000637" target="_blank">UMP-CMP kinase</a></li></ul></td><td><a href="/metabolites/DBMET00858">Gemcitabine diphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1271">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00858">Gemcitabine diphosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003106" target="_blank">Nucleoside diphosphate kinase A</a></li></ul></td><td><a href="/metabolites/DBMET00859">Gemcitabine triphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1272">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (</td></tr><tr><th>Half life</th><td>Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.</td></tr><tr><th>Clearance</th><td><ul>
	<li>92.2 L/hr/m2 [Men 29 yrs]</li>
	<li>75.7 L/hr/m2 [Men 45 yrs]</li>
	<li>55.1 L/hr/m2 [Men 65 yrs]</li>
	<li>40.7 L/hr/m2 [Men 79 yrs]</li>
	<li>69.4 L/hr/m2 [Women 29 yrs]</li>
	<li>57 L/hr/m2 [Women 45 yrs]</li>
	<li>41.5 L/hr/m2 [Women 65 yrs]</li>
	<li>30.7 L/hr/m2 [Women 79 yrs]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD<sub>50</sub>=500 mg/kg (orally in mice and rats)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Gemcitabine Action Pathway</td><td>Drug action</td></tr><tr><td>Gemcitabine Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00603?highlight%5Bcompounds%5D%5B%5D=DB00441&amp;highlight%5Bproteins%5D%5B%5D=DB00441">SMP00603</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Ribonucleoside-diphosphate reductase large subunit<br>Gene symbol: RRM1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P23921" target="_blank">P23921 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3177016" target="_blank">rs3177016 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A Allele</td><td>Neutropenia</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17602053" target="_blank" title="Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, Roh JK, Chung HC: An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30.">17602053 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Ribonucleoside-diphosphate reductase large subunit<br>Gene symbol: RRM1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P23921" target="_blank">P23921 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1042858" target="_blank">rs1042858 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G Allele</td><td>Neutropenia</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17602053" target="_blank" title="Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, Roh JK, Chung HC: An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30.">17602053 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9814</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9693</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8317</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9557</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.939</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8634</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8484</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6016</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8958</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8633</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8787</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8478</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9032</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8862</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6793
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8286
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9948
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1220 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9948
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8314
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Teva parenteral medicines inc</li>
<li>Eli lilly and co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.lilly.com">Eli Lilly &amp; Co.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>200 mg, 1 g, 2 g</td></tr><tr><td>Solution</td><td>Intravenous</td><td> 200 mg/5.26 mL; 1 g/26.3 mL; 2 g/52.6 mL</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Gemcitabine may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Gemcitabine may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00006">Bivalirudin</a></td><td>Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Gemcitabine may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Paclitaxel increases the effect/toxicity of gemcitabine</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Co-administration of Temsirolimus and Gemcitabine may result in serious adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Gemcitabine may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>